As of 2025-10-31, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 477.44 mil USD. SAGE's TTM EBITDA according to its financial statements is -294.68 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 15.2x | 13.8x |
| Forward P/E multiples | 20.1x - 43.4x | 31.8x |
| Fair Price | (93.27) - (70.27) | (105.83) |
| Upside | -1174.5% - -909.6% | -1319.2% |
| Date | EV/EBITDA |